Zachary BrennanSenior Editor When AbbVie CEO Richard Gonzalez sat before the House Committee on Oversight last week, calmly fending off questions about his mega-blockbuster Humira and its fortress of patents, the fate of any competition entering the US market before 2023 seemed all but sealed. But what none of the representatives nor their 57-page report...